Anyone have experience/thoughts on the iGenomX Riptide system? Worth checking out..?
-
-
We have not tried it, but it looks promising for for very large projects - meaning hundreds of samples? -
We just did a Zoom call with them, and I was very impressed. We will order one of their kits when we get in a large number of bacterial DNAs. They are working on RNA kits, but don't offer them yet. They plan to have a ribodepletion kit too, that is very interesting, but I don't think I can describe it in a public forum yet.
The kits have a one year shelf life too (which is great), but you pretty much have to use them in batches of 96.
Although even if you only use 48 samples and toss the rest of that plate, the cost would be in the $20 range per sample... not bad if it works.Comment
-
Pros: high throughput, low cost, simple workflow, quality base calls and mapping rates, tunable for GC, customizable (can add targeted primers), inputs from 1-200+ ng and can accommodate dsDNA or ssDNA inputs (first strand cDNA, WGA, bisulfite converted).
Cons: Current version does not use UDIs (it is dual index, just not unique dual), uses priming + amplification so produces some peaks and valleys in coverage, current format has marginally lower complexity per sample library (so not recommended for low frequency somatic variant detection). Read count correlates with input.
best practices: works best for 96 (or more) samples of same species, same template source.
Common applications: microbial WGS, meta genomic/ microbiome screening, PCR amplicons, and skim-seq / GBS.Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment